Invivoscribe Claims Win in FLT3 Patent Case | GenomeWeb

NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said that a German court has ruled in its favor in a patent dispute over FLT3 testing technology.

The San Diego-based firm said that the German District court in Munich found MLL Muenchner Leukaemielabor GmbH Laboratories guilty of infringing a patent held by Takara Bio and licensed exclusively to Invivoscribe. It also noted that the court declined to stay enforcement of its decision.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.